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Background: Chemical crosslinking is the most straightforward method to produce bispecific antibodies (BsAb) for
arming ex vivo activated cytotoxic T lymphocytes. However, heterogeneous polymers are produced by chemical
crosslinking. Currently, it is not known under what circumstances or to what extent further purification is needed.
Results: In this study, we purified Traut’s Reagent-Sulfo-SMCC crosslinked anti-CD3 × anti-HER2 by size-exclusion
column chromatography and compared the capacity of the crude and the purified forms of the BsAb in enhancing
cytokine-induced killer (CIK) cell-mediated cytotoxicity in vitro. We found that the purified BsAb assisted CIK cells
more efficiently than the crude form only when the spontaneous cytotoxicity of the CIK cells was relatively low;
otherwise, the two forms performed almost identically.
Conclusions: For the CIK cells of low spontaneous cytotoxicity, purified BsAb is a more powerful substitute for
crude BsAb in enhancing their killing efficacy. However, that purification of BsAb is not necessary for robust CIK
cells. This phenomenon also corroborates that CIK-mediated cytotoxicity is highly dependent on cell contact.
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The concept of using hybrid antibodies to direct the
cytotoxicity of effector cells to their intended target
emerged in the 1980s [1]. The hybrid antibodies, pro-
duced by chemical crosslinking [2,3] or hybrid hybrid-
omas [4,5] possess at least two different Fab fragments
simultaneously, thus bridging effector and target cells by
antibody-antigen recognition. Consequently, these are
also called bispecific antibodies (BsAbs).
In 1990, Nitta et al. first combined cytokine-induced im-
mune effector cells and BsAbs to treat malignant glioma.
Compared with untreated lymphokine-activated killer (LAK)
cells, BsAb-armed LAK cells efficiently eradicated glioma
cells and prolonged patients’ lifespan. Subsequently, several
groups applied BsAbs to direct various versions of LAK
cells towards ovarian carcinoma [6], colon carcinoma* Correspondence: caoxt@immunol.org; wei.ge@chem.ox.ac.uk
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unless otherwise stated.[7], small-cell lung carcinoma [8], breast cancer [9] or
B-lymphoma [10]. Some of these therapies have entered
clinical trials [11].
In past decades, novel methods have been developed
to produce BsAbs, including diabodies [12], and duobo-
dies [13]. However, direct chemical crosslinking of two
monoantibody populations, which involves the use of
existing antibodies and does not involve additional bio-
engineering, is still the most straightforward and widely
used method [14-17]. Although there were once a concern
for recruiting Fcγ receptor cells [18], they are tolerable at
the dose used to arm LAK-like cells and experience of the
trifunctional antibody drug Ertumaxomab indicates a po-
tential benefit [19].
Because site-specific conjugation methods are unavail-
able, the product of chemical crosslinking is always het-
erogeneous, with more than 50% of the total protein mass
of the product reported to comprise IgG monomers [9].
These will occupy binding sites but not bridge effector
and target cells. Therefore, theoretically when the con-
jugation product is applied as a whole, the existence of
monomers will interfere with the performance of IgGThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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binding sites on cells and the threshold of bridge number
to trigger cytotoxicity also influence the performance of the
chemical conjugate, we need to assess to what extend the
monomers influence the performance and whether further
purification of the chemical conjugate is necessary or not.
Here, we crosslinked anti-CD3 and anti-HER2 chem-
ically and purified the crude conjugation product with
size-exclusion chromatography to an IgG dimer purity
of >70%. The potency of the crude and the purified
BsAb was then assessed in directing the cytotoxicity of
cytokine-induced killer (CIK) cells [20] against human
SK-BR-3 breast cancer cells. The purified BsAb potentiated
CIK cells of poor spontaneous cytotoxicity more efficiently
than the crude form, while their performance was indistin-
guishable when applied to CIK cells of robust spontaneous
cytotoxicity. These results suggest that further purification
to remove IgG monomers from chemically conjugated
BsAb is always unnecessary; however, when spontaneous
cytotoxicity of CIK cells is relatively weak, purified BsAb
may enhance the performance more efficiently. Our find-
ings also indicate that the mechanism by which CIK cells
kill tumor cells is highly dependent on cell membrane
adherent molecules; thus, variation in the spontaneous
cytotoxicity of CIK cells among different donors or culture
times is influenced by the expression of these molecules.
Results
Traut’s reagent and sulfo-SMCC efficiently crosslink
anti-CD3 and anti-HER2
The sulfhydryl-mediated reaction was employed to cross-
link anti-CD3 and anti-HER2. For maximal crosslinking
efficiency, several crosslinker pairs were screened.
Traut’s Reagent or SATA were conjugated with anti-
CD3 to introduce sulfhydryls, while Sulfo-SMCC, Sulfo-
LC-SPDP or Sulfo-SIAB were conjugated with anti-HER2
to introduce functional groups that react with sulfhydryls.Figure 1 Chemical crosslinking of anti-CD3 and anti-HER2. (A) Native e
unconjugated control. 10 μg protein per lane. (B) Native electrophoresis of cr
protein per lane. (C) Native electrophoresis of Traut’s-SMCC-crosslinked anti-C
(r. t, room temperature). 10 μg protein per lane.After conjugation, no molecular weight shift of the mono-
mer band or obvious polymerization was observed in the
product (Figure 1A). A faint band with a migration pattern
corresponding to that of an IgG dimer was detected in
anti-HER2 samples, but was shown to represent less than
1% of the total protein by densitometry (Figure 1A).
After conjugation, equal molar quantities of sulfhydryl-
containing anti-CD3 and sulfhydryl-reacting anti-HER2
were mixed with all combinations of the crosslinkers and
the crosslinking products were resolved by native protein
electrophoresis. Because crosslinkers reacted with IgG
in 5-fold or more molar excess, each IgG molecule was
linked with multiple sulfhydryls or sulfhydryl-reacting
functional groups. As expected, heteroconjugation of anti-
CD3 × anti-HER2 produced a series of molecules includ-
ing monomers, dimers, and trimers (Figure 1B).
Anti-CD3 × anti-HER2 BsAb is designed to mediate con-
tact between cytotoxic T cells and tumor cells expressing
high levels of HER2; thus, anti-CD3 × anti-HER2 dimers
are the ideal effectors. Among the combinations of cross-
linkers, Traut’s-SMCC produced the largest proportion of
dimers (Figure 1B). The dimer yield of Traut’s-SPDP was
comparable to that of Traut’s-SMCC (Figure 1B); however,
crosslinking involving SPDP requires an overnight incuba-
tion, which is much longer than that required for SMCC.
Products of SATA crosslinking contained less monomers
but more insoluble aggregates than those of Traut’s
Reagent, which indicated over-crosslinking. Unexpect-
edly, bands of aberrant molecular weight were detected
among the products of Sulfo-SIAB crosslinking, which
might be a consequence of the reagent itself.
Based on the crosslinking efficiency, the combination
of Traut’s Reagent and Sulfo-SMCC was used for BsAb
production in the following experiments.
Traut’s-SMCC-conjugated BsAb was stable during a 3-
month storage at room temperature, 4°C, -20°C or -80°C
(Figure 1C).lectrophoresis of crosslinker-conjugated IgG monomer. Input represents
osslinked anti-CD3 × anti-HER2 with combinations of crosslinkers. 10 μg
D3 × anti-HER2 following storage under various conditions for 3 months
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conjugation product to a dimer purity of >70%
As shown in Figure 1B, IgG monomer comprised approxi-
mately 40% of the crosslinking product. The monomer in-
terferes with anti-CD3 × anti-HER2 dimer bridging of CIK
cells and tumor cells by occupying CD3 or HER2 on the
cell membrane. To maximize the efficacy of the product,
IgG monomer was removed by size-exclusion chromatog-
raphy. In resolution using a Superdex 200 10/300 GL
column, the monomer was well separated from dimer and
polymer (Figure 2A).
Gel filtration fractions were evaluated by native elec-
trophoresis (Figure 2B), and the pooled Fractions B11,
B12 and C1 were designated as “purified BsAb”. As
shown in Figure 2C, the dimer proportion in the purified
product, which reached >70% according to densitometric
analysis, was approximately twice that in the crude
product. However, the yield of purified BsAb was only
approximately 15%.
Bio-Rad gel filtration standards were separated on the
same column to determine the molecular weight of the
IgG dimer and monomer. The molecular weight and
the elution volume of each peak were recorded to estab-
lish a standard curve (Additional file 1: Figure S1). Using
the formula of the standard curve, the molecular weightFigure 2 Purification of crude BsAb by size-exclusion column chroma
Superdex 200 10/300 GL. (B) Native electrophoresis of Fractions B6 to C4. E
Native electrophoresis of anti-CD3/anti-HER2 equal molar mixture (mix), cruof the monomer was calculated as 130.60 kDa (Additional
file 1: Table S3), which was slightly smaller than the ex-
pectation of 150 kDa; while that of the dimer was 378.48
kDa (Additional file 1: Table S3), which was larger than
the expectation of 261.20 kDa but very close to that of the
trimer (391.80 kDa). It is impossible for the crosslinking
reaction to form a trimer without forming a dimer; thus,
we did not consider that the peak corresponded to a tri-
mer but instead, speculated that the shift resulted from an
extended molecular shape.
Purified BsAb assisted the CIK cells of poor spontaneous
cytotoxicity more efficiently than did crude BsAb
To evaluate the efficacy of purified BsAb in enhancing
CIK cell cytotoxicity, in vitro cytotoxicity assays were
carried out using the SK-BR-3 breast cancer cell line as
targets. A single batch of CIK cells in continuous culture
was used in all the assays described.
As shown in Figure 3A, the mixture of anti-CD3 and
anti-HER2 did not direct CIK cell cytotoxicity against
SK-BR-3 cells, while both crude and purified BsAb en-
hanced the cytotoxicity against these targets. When less
than 50 ng of BsAb per 106 effector cells was applied in
an effector cell vs. target cell (E:T) ratio of 5, BsAb
assisted CIK cell cytotoxicity in a dose-dependent effect.tography. (A) UV profile of Traut’s-SMCC-crosslinked BsAb running in
qual proportions (2%) of each fraction were loaded in each well. (C)
de crosslinking product (crude) and purified BsAb (purified).
Figure 3 BsAb-armed CIK-mediated cytotoxicity against SK-BR-3. (A) Specific cytotoxicity mediated by CIK cells armed with 0–50 ng antibody
per 106 cells (mix, anti-CD3/anti-HER2 equal molar mixture). (B) Specific cytotoxicity of the same batch of CIK cells on two consecutive days. The results
shown in the figures were representative of at least two independent experiments.
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the effects mediated by purified and crude BsAb.
It is well-recognized that the spontaneous cytotoxicity of
a single batch of CIK cells in continuous culture varies on
a daily basis [9], and that the cytotoxicity of CIK cells varies
from donor to donor [21]. In further studies, we found that
the spontaneous cytotoxicity of CIK cells varied between
the crude and the purified BsAb. As shown in Figure 3B,
assays performed with the CIK cells on two consecutive
days revealed that, when the spontaneous cytotoxicity was
negligible, the CIK cells armed with purified BsAb exhib-
ited at least two-fold cytotoxicity compared with that when
armed with crude BsAb (t-test: p < 0.05); however, on the
second day when the spontaneous cytotoxicity was as high
as 10%, there was no significant difference between the ef-
fects of the purified and crude BsAb (t-test: p > 0.05). Fur-
thermore, we found that spontaneous cytotoxicity was also
associated with the saturating amount of BsAb. When the
spontaneous cytotoxicity of CIK was approximately 10%,
5 ng BsAb was enough to saturate 106 CIK cells. However,
when the spontaneous cytotoxicity was low, at least 25 ng
BsAb was required for saturation.We also tested the stability of the purified BsAb following
lyophilization. Purified BsAb in PBS was directly lyoph-
ilized and reconstituted with ddH2O. The lyophilization-
reconstitution cycle caused approximately 10% soluble
protein loss (data not shown); however, the efficacy of
reconstituted BsAb was slightly higher than that of the
original sample (Additional file 1: Figure S2). This may be
because polymers are more prone to precipitation follow-
ing lyophilization than oligomers.
Discussion
Chemical crosslinking is the most convenient and rapid
method to produce BsAb. However, the product of
chemical crosslinking comprises a heterogeneous series
of conjugates, including IgG monomers, heterodimers,
heterotrimers and so on. The mixture of anti-CD3 and
anti-HER2 did not enhance CIK cytotoxicity cell against
SK-BR-3 (Figure 3A). Furthermore, the dose of BsAb
used in cell-mediated cytotoxicity assays is non-toxic to
tumor cells (Additional file 1: Figure S3). Therefore, the
only function of BsAb should be establishing contact
between the effector and target cells. A heterodimer may
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cells at most. In contrast, monomers affect the function
of dimers by occupying cell surface molecules and con-
jugates of three or more IgGs may lead to ineffective
contact between the same cell populations. In this re-
port, we purified chemically conjugated BsAb and ele-
vated the purity of the heterodimer to more than 70%.
We predicted that the purified BsAb would enhance
CIK cell-mediated cytotoxicity by two-fold compared
with that of the crude form. However, our results dem-
onstrated that the efficacy of the purified BsAb was asso-
ciated with the capacity for spontaneous cytotoxicity of
CIK cells. When the spontaneous cytotoxicity of CIK
cells was undetectable, the purified BsAb potentiated the
effects of CIK cells much more efficiently than did the
crude form; however, when the spontaneous cytotoxicity
of CIK cells was as high as 10%, the purified and the crude
BsAb performed almost identically. This phenomenon in-
dicates that CIK cell-mediated cytotoxicity to tumor cells
is highly dependent on cell contact.
It has long been observed that the cytotoxicity of a sin-
gle batch of CIK cells in continuous culture varies day by
day [9]. CIK cells are heterogeneous. The major cytotoxic
population of CIK cells comprises CD3+CD56+ cells
[22-24]. As the cytotoxicity assays were performed in
consecutive two days (Figure 3B), the variation in the
spontaneous cytotoxicity was unlikely to be due to the
propagation of cytotoxic cells but is more likely to be
affected by the expression of certain cell surface adher-
ent molecules. Based on this assumption, we propose
that cells with robust capacity for spontaneous cyto-
toxicity possess abundant adherent molecules, thus,
allowing for saturated contact between CIK cells and
tumor cells. This would account for the observation
that the purified and crude forms of BsAb performed
almost identically. However, when the capacity for
spontaneous cytotoxicity of cells is undetectable, indi-
cating that the cells possess few adherent molecules,
the contact between CIK cells and tumor cells is far
from being saturated. Thus, when applied in the same
dose, the purified BsAb mediated more CD3-HER2
bridges than the crude, which accounts for the greater
potentiation of CIK cell cytotoxicity mediated by the
purified BsAb compared with that mediated by the
crude product.
In summary, our study demonstrates that the purified
chemically conjugated BsAb assists the CIK cells of poor
spontaneous cytotoxicity more efficiently than the crude,
which implicates that for the cancer patients whose au-
tologous CIK cells are of low spontaneous cytotoxicity,
the purified BsAb is a more powerful arming reagent
substitute for the crude BsAb. If the spontaneous cyto-
toxicity of CIK cells is relatively high, purification of
chemically conjugated BsAb is not necessary.Material and methods
Cells
CIK cells were prepared as described in Schmit-Worf
et al. [20] with slight modifications. Briefly, lymphocytes
were isolated from peripheral blood obtained from
cancer patients by Ficoll gradient centrifugation. At
Day 0, non-adherent lymphocytes were adjusted to a
final concentration of 1–3 × 106 cells/mL and stimu-
lated with 300–500 U/mL human interleukin-4 (IL-4) and
1,000 U/mL interferon-γ (IFN-γ) for 24 h. Then cells
were treated with 50–100 ng/mL soluble anti-CD3
(TONBO Biosciences, San Diego, CA, US, clone: OKT3)
and 100 U/mL human recombinant interleukin-1α
(rIL-1α) for 48 h. Medium supplemented with recom-
binant interleukin-2 (rIL-2) was refreshed every three
days. Experiments were carried out with these CIK cells
at approximately Day 14.
The human breast cancer cell line SK-BR-3 was pur-
chased from the Cell Resource Center, Institute of Basic
Medical Sciences, Chinese Academy of Medical Sciences.
Antibody chemical crosslinking
Mouse monoclonal anti-CD3 antibody was purchased
from TONBO Biosciences (clone: OKT3, REF: 40-0037-
U500).
Humanized anti-HER2 monoantibody was purchased
from Roche (trastuzumab/Herceptin®).
Traut’s Reagent (2-Iminothiolane · HCl), N-Succinimidyl




aminobenzoate (Sulfo-SIAB) were purchased from Pierce
Biotechnology, Thermo SCIENTIFIC.
Buffer changing and protein desalting was performed
with Zeba Spin Desalting Columns (MWCO: 7 kDa,
Thermo SCIENTIFIC). IgG was concentrated with Ami-
con Ultra Centrifugal Filters. Crosslinking reactions were
performed on an Eppendorf Thermomixer at 300 rpm.
Chemical crosslinking of antibodies was carried out fol-
lowing the manufacturer’s instructions provided with the
crosslinking reagents. Detailed conditions for the conjuga-
tion of crosslinker and IgG are shown in Additional file 1:
Table S1. Conditions for heterocrosslinking of two conju-
gated IgGs are shown in Additional file 1: Table S2.
To evaluate BsAb in native electrophoresis, samples were
mixed with one third volume of 4× NuPAGE LDS Sample
Buffer (Novex, Life Technologies), electrophoresed in a
NuPAGE 4–12% Bis-Tris Gel (Novex, Life Technologies)
and visualized with Commassie brilliant blue staining.
Size-exclusion chromatography
Crude BsAb (6 mg) was loaded onto a Superdex 200
10/300 GL gel filtration column (GE Healthcare) attached
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#1890535) was used as running buffer. Each fraction com-
prised 0.5 mL.
For molecular weight calculations, a gel filtration stand-
ard (BIO-RAD, #151-1901) was loaded onto the same col-
umn and run under the same conditions. The molecular
weight and the corresponding elution volume of peaks
was recorded to formulate a standard curve using the
regression analysis function of Microsoft Excel 2013.
The molecular weight of BsAb was estimated from the
standard curve.
Cytotoxicity assay
In vitro cytotoxicity assays were carried out with the
CytoTox 96® Non-Radioactive (LDH) Cytotoxicity Assay
Kit (Promega #G1780) following the manufacturer’s
instructions.
To determine cell-mediated cytotoxicity, CIK cells were
suspended in modified RPMI-1640 medium (HyClone
#SH30809.01B) containing 5% fetal bovine serum (FBS,
Gibco #10099-141). The intended amount (0-50 ng per
106 cells) of BsAb was added to the suspension, and 30
minutes later non-coupled BsAb was washed out with the
same medium. BsAb-armed CIK cells (1 × 105) and 2 × 104
SK-BR-3 cells suspended in the medium were plated into
each well of a 96-well plate. After a 6-hour incubation at
37°C, 50 μL supernatant from each well was used in the
LDH assay. OD490 was measured with the Varioskan Flash
Multimode Reader (Thermo SCIENTIFIC) to calculate
CIK-mediated specific cytotoxicity towards SK-BR-3.
To determine antibody-mediated cytotoxicity, SK-BR-3
cells (2 × 104 cells/well) were plated into 96-well plates.
50 ng of the anti-CD3/anti-HER2 mixture, crude or
purified BsAb was added to the wells immediately. After
a 6-hour incubation at 37°C, 50 μL supernatant from
each well was used in the LDH assay. OD490 was mea-
sured to calculate cytotoxicity towards SK-BR-3.
Densitometry
Densitometry of stained protein bands was performed
with ImageJ software [25].
Ethical approval
The protocol was approved by Ethics Committee of
Institute of Basic Medical Sciences, Chinese Academy of
Medical Sciences (reference number: CAMS012-2014).
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